Relay Therapeutics, Inc. (RLAY) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Relay Therapeutics, Inc. (RLAY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Relay Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical trial collaboration with Pfizer for combination therapy in metastatic breast cancer, initiated June 2024, introducing additional regulatory and safety risks
- • Increased risk of clinical trial delays from FDA potentially requiring additional trials or changing approval conditions due to novel mechanisms of action
- • FDA may require companion diagnostics for RLY-2608 biomarker-defined population, failure of third-party diagnostics could delay regulatory approval
- • Near-term risk of slower patient enrollment due to competitive clinical trial environment and specific eligibility criteria, impacting trial timelines
- • Financial risk from increased costs if clinical trials face delays, with potential impact on exclusive commercialization period and competitive positioning
Get deeper insights on Relay Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.